Table 1.
Clinical characteristics
| RACRS (n = 206) | LCRS (n = 172) | P value | ||
|---|---|---|---|---|
| Sex, % (n) | ||||
| Male | 66.5% (137) | 57.6% (99) | 0.074 | |
| Female | 33.5% (69) | 42.4% (73) | ||
| BMI, % (n) | 0.407 | |||
| < 18 | 1.0% (2) | 2.3% (4) | ||
| 18–25 | 38.3% (79) | 36.0% (62) | ||
| 25–30 | 43.2% (89) | 39.0% (67) | ||
| > 30 | 17.5% (36) | 22.7% (39) | ||
| Age, mean ± SD | 68.32 ± 10.02 | 70.11 ± 9.96 | 0.083 | |
| ASA grade, % (n) | 0.136 | |||
| ASA 1 | 23.3% (48) | 15.7% (27) | ||
| ASA 2 | 56.8% (117) | 57.6% (99) | ||
| ASA 3 | 19.9% (41) | 26.2% (45) | ||
| ASA 4 | 0.0% (0) | 0.6% (1) | ||
| History of abdominal surgery, %(n) | 28.2% (58) | 27.9% (48) | 0.548 | |
| cTNM classification, % (n/ntotal)a | 0.546 | |||
| I | 15.8% (12/76) | 13.3% (4/30) | ||
| II | 14.5% (11/76) | 23.3% (7/30) | ||
| III | 69.7% (53/76) | 63.3% (19/30) | ||
| Missing data, n | 1 | 4 | ||
| Neoadjuvant therapy, %(n/ntotal)b | 63.6% (49/77) | 55.9% (19/34) | 0.440 | |
| Chemotherapy | 28.6% (22/77) | 20.6% (7/34) | 0.378 | |
| Radiotherapy | 62.3% (48/77) | 55.9% (19/34) | 0.522 | |
BMI body mass index, ASA American Society of Anesthesiologist, cTNM clinical tumor-node-metastases stage, RACRS robot-assisted colorectal surgery, LCRS laparoscopic colorectal surgery
a Clinical cancer stage of patients with rectal cancer, based on pre-operative MRI
b Rectal cancer group